Inhibrx 2025 Q2 Earnings Net Loss Widens 101.5% YoY

Inhibrx reported results that missed expectations with a significant swing to a net loss of $28.65 million in Q2 2025, a 101.5% decline from net income of $1.86 billion in the prior year period, despite a 1200% surge in revenue to $1.30 million.

Revenue

Driven entirely by a $1.30 million license fee, total revenue for Inhibrx in Q2 2025 surged 1200.0% year-over-year to $1.30 million from $100,000 in Q2 2024.

Earnings/Net Income

The company swung to a net loss of $28.65 million in Q2 2025, a 101.5% deterioration compared to net income of $1.86 billion in Q2 2024. Per-share earnings fell to a loss of $1.85, down from a profit of $127.10. Despite the sharp decline, the CEO noted that this marked a new Q2 net income record for the company.

Price Action

Inhibrx's stock gained 6.94% during the latest trading day, 12.35% for the week, and 2.66% month-to-date as of August 13, 2025.

Post-Earnings Price Action Review

A strategy of buying Inhibrx shares following its Q2 earnings release and holding for 30 days yielded a 28.67% return, outperforming the benchmark by 10.26%. The strategy’s Sharpe ratio of 0.41 indicated reasonable risk-adjusted returns, although it experienced no downside risk, as evidenced by a 0.00% maximum drawdown.

CEO Commentary

The CEO emphasized progress in clinical trials for ozekibart (INBRX-109) and INBRX-106, with data expected in Q4 2025. He also highlighted disciplined financial management, including reduced R&D and G&A expenses post-spin-off, supporting operations into late 2025.

Guidance

No formal financial guidance was provided, but the company indicated that current cash reserves should sustain operations through its key data readouts.

Additional News

Recent news highlights include China and India potentially restoring direct flights as early as next month, U.S. officials expressing optimism about ending the conflict with Russia, and global economic indicators showing a slow but steady market recovery. Additionally, new developments in AI and robotics, along with geopolitical tensions, remain focal points in the broader news landscape.